logo
Plus   Neg
Share
Email

FDA Nixes Expanded Dacogen Use : Astex Pharma

dacogen-030712.jpg

Astex Pharmaceuticals Inc. (ASTX) announced Tuesday that the FDA has declined to approve Dacogen for Injection in the additional indication of acute myeloid leukemia in elderly patients who are not considered candidates for induction therapy.

Dacogen is currently approved for the treatment of myelodysplastic syndrome, which is a disease of the blood and bone marrow, and is available in more than 30 countries worldwide including, key markets such as the United States, Brazil, China, India, Russia and Turkey.

Dacogen was licensed by Astex Pharma to MGI Pharma Inc., in August 2004, which in turn, sub-licensed the drug to Janssen-Cilag, a Johnson & Johnson company in July 2006. MGI Pharma was acquired by Eisai Corp of North America in January 2008.

The supplemental New Drug Application for Dacogen for patients with acute myeloid leukemia in adults 65 years of age or older who are not considered candidates for induction therapy, which was submitted by Eisai, was based on a phase III clinical trial (DACO-016) data.

An FDA panel, which reviewed the application, voted 10 to 3 against the new use for Dacogen last month, saying that the drug did not have a favorable benefit-risk profile in the acute myeloid leukemia setting.

In line with the panel's recommendations, the FDA has also declined to approve Dacogen for additional use on the grounds that the pre-specified analysis of the primary endpoint in the study (DACO-016) did not demonstrate statistically significant superiority of Dacogen over the control arm.

The proposal for Dacogen's approval for the treatment of elderly Acute Myeloid Leukemia is under review in the European Union, and the European Medicines Agency is expected to announce its decision later this year.

ASTX closed Tuesday's trading at $1.83, down 4.19%, on a volume of 571,232 shares.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
A $716 billion defense policy bill easily cleared the Senate on Monday, although the legislation must still be reconciled with the version previously approved by the House. The Senate voted 85 to 10 in favor of the National Defense Authorization Act, which authorizes U.S. military spending for fiscal 2019. Voip-Pal.com Inc. has filed a lawsuit against Amazon Inc., accusing Alexa's calling and messaging services of infringing its patents. The lawsuit, filed by Voip-Pal in the U.S. District Court in Nevada, accuses Amazon's Alexa calling and messaging system of using Voip-Pal's patented technologies to direct voice/video calls and voice messages to both Amazon subscribers and non-subscribers. Canada is a step closer to becoming the first G-7 nation to legalize marijuana nationwide after the House of Commons voted to allow recreational use. The bill will now go back to the country's Senate, which had already approved a version of the bill. On Monday, the House of Commons voted 205 to 82 in favor of the Bill C-45, known as the Cannabis Act.
Follow RTT